Financial Results for the Year Ended March 31, 2013 <Supplement>

As of May 8, 2013

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for FY2012 Ended March 31, 2013 and Forecasts for FY2013

1. Summary of Financial Results for FY2012
2. Summary of Forecasts for FY2013 3. Dividends … … 2

2 Consolidated Financial Indicators for FY2012

1. Profit and Loss … … 3
   (1) Profit anf Loss (2) Sales by Business Segments
   (3) Cost of Sales and SG&A Expenses … … 3
   (4) Non-operating Income and Expenses (5) Extraordinary Income and Loss (6) Taxes … … 4
   (7) Sales of Main Products … … 5
2. Financial Statement … … 6
   (1) Balance Sheet … … 6
   (2) Cash Flow Statement … … 7
   (3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems (4) Depreciation Costs … … 8
3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries … … 8

3 Forecasts for FY2013 Ending March 31, 2014

(1) Consolidated Forecasts of Profit and Loss (2) Sales Forecasts by Segments … … 9
(3) Forecasts of Cost of Sales and SG&A Expenses … … 9
(4) Sales Forecasts for Main Products … … 10
(5) Forecast for Investment in Property, Plant and Equipment and Information Systems … … 11
(6) Forecasts for Depreciation Costs … … 11

4 Five-Year Financial Data

(1) Profit and Loss (2) Balance Sheet (3) Other Financial Data (4) Number of Employees … … 12

5 Quarterly Trend

(1) Profit and Loss … … 13
(2) Sales of Main Products … … 14

6 State of New Product Development (as of May 8, 2013)

1. Pipeline in Japan … … 15
   (1) New Molecular Entities (2) Additional Indications … … 15
2. Pipeline Overseas … … 16
   (1) New Molecular Entities … … 16
3. Licensing-out … … 17
4. Changes Since Previous Announcement on Feb. 1, 2013 … … 18
   (1) In-house Development (2) Licensing-out … … 18
5. Additional Information for State of New Product Development … … 19
   (1) New Molecular Entities in Japan … … 19
   (2) Additional Indications in Japan … … 19
   (3) New Molecular Entities Overseas … … 20
   (4) Licensing-out … … 20

7 Others

1. Subsidiaries and Affiliated Companies … … 21
   (1) Number of Subsidiaries and Affiliated Companies (2) Consolidated Subsidiaries
   (3) Affiliated Companies Accounted for by the Equity Method … … 21
2. Status of Shareholders … … 22
   (1) Number of Outstanding Shares
   (2) Status of Major Shareholders (3) Ownership and Distribution of Shares
   (4) Trend of Divended and Stock Price … … 22

Reference

Major Ethical Drugs / News Releases … … 23

1 Summary of Financial Results for FY2012 Ended March 31, 2013 and Forecasts for FY2013

(Amounts less than ¥100 million are rounded.)

1. Summary of Financial Results for FY2012

[Billion yen]

Net Sales	419.2	Y-on-Y	12.0	3.0 %
Pharmaceuticals	414.7	Y-on-Y	17.1	4.3 %
Other Businesses	4.5	Y-on-Y	(5.1)	(53.2 %)

In the pharmaceuticals segment, net sales were ¥414.7 billion, up 4.3%, or ¥17.1 billion, year-on-year.
Although there were the NHI drug price revisions implemented in April 2012 and the growing impact of generics, in domestic sales of ethical drugs, continued favorable sales growth was recorded by Remicade, an anti-TNF α monoclonal antibody, and new drugs which were launched between the previous fiscal year and the current fiscal year made contributions. As a result, the domestic sales of ethical drugs were ¥356.6 billion, up 0.3%, year-on-year.
Overseas sales of ethical drugs were ¥23.4 billion, up 26.7%, year-on-year, and sales of OTC products decreased 2.1%, to ¥5.3 billion.
Sales of others in pharmaceuticals increased 61.3%, year-on-year, to ¥29.5 billion, due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis.
In others, sales were down 53.2%, or ¥5.1 billion, year-on-year, due to the transfer of fine chemical operations in July, 2012.

The Principal Products and Businesses in Each Business Segment
Pharmaceuticals: Ethical drugs, over-the-counter-drugs
Other businesses: Fine chemicals, real-estate leasing, information services, advertising, etc

[Billion yen]

Operating Income	69.0	Y-on-Y	(0.1)	(0.1 %)

Operating income was ¥69.0 billion, on the same level as the previous year.
Although net sales increased ¥12.0 billion, year-on-year, gross profit decreased ¥2.1 billion, year-on-year, to ¥252.8 billion due to the influence of NHI drug price revisions and other factors. The cost of sales ratio worsened by 2.3 percentage points year-on-year.
SG&A expenses were down ¥2.0 billion, year-on-year, to ¥183.8 billion, due to the decrease in R&D expenses.

[Billion yen]

Ordinary Income	69.4	Y-on-Y	0.6	0.9 %
Net Income	41.9	Y-on-Y	2.9	7.4 %

Ordinary income was up 0.9%, or ¥0.6 billion, year-on-year, to ¥69.4 billion, and net income was up 7.4%, or ¥2.9 billion, year-on-year, to ¥41.9 billion.
Extraordinary income was ¥4.2 billion, including gain on sales of property, plant and equipment. In the previous fiscal year, extraordinary income was ¥1.2 billion, including gain on sales of property, plant and equipment.
Extraordinary loss was ¥5.9 billion, including loss on business integration of the plasma fractionation operations of ¥2.3 billion and a provision of reserve for HCV litigation of ¥2.0 billion. In the previous fiscal year, extraordinary losses were ¥6.1 billion, including loss on impairment of fixed assets of ¥3.3 billion and loss on valuation of investment in securities of ¥2.2 billion. As a result, extraordinary loss/income improved ¥3.3 billion, year-on-year.

2. Summary of Forecasts for FY2013

[Billion yen]

Net Sales	417.0	Y-on-Y	(2.2)	(0.5 %)
Operating Income	70.0	Y-on-Y	1.0	1.5 %
Ordinary Income	71.5	Y-on-Y	2.1	3.0 %
Net Income	44.0	Y-on-Y	2.1	5.0 %

3. Dividends

	FY2013 (Estimate)		FY2012	
	End of 1st Half	For the Year	End of 1st Half	For the Year
Dividends per Share (¥)	20	40	20	40
Dividends Payout Ratio	-	51.0%	-	53.6%
prior to amortization of goodwill	-	41.5%	-	43.2%

2 Consolidated Financial Indicators for FY2012

(Amounts less than ¥100 million are rounded.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	FY2012	Y-on-Y			Comparison to Forecasts		
		FY2011	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %
Net sales	**419.2**	407.2	12.0	3.0	425.0	(5.8)	(1.4)
Cost of sales	**166.4**	152.3	14.1	9.3	167.0	(0.6)	(0.4)
Sales cost ratio	**39.7%**	37.4%			39.3%		
Gross operation profit	**252.8**	254.9	(2.1)	(0.8)	258.0	(5.2)	(2.0)
SG&A expenses	**183.8**	185.8	(2.0)	(1.1)	188.0	(4.2)	(2.2)
% of net sales	**43.9%**	45.6%			44.2%		
Operating income	**69.0**	69.0	(0.1)	(0.1)	70.0	(1.0)	(1.5)
Ordinary income	**69.4**	68.8	0.6	0.9	71.0	(1.6)	(2.3)
Extraordinary income and loss	**(1.7)**	(5.0)	3.3	-	(5.0)	3.3	-
Net income	**41.9**	39.0	2.9	7.4	40.5	1.4	3.4

(2) Sales by Business Segments

[Billion yen]

	FY2012	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		FY2011	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %	
Pharmaceuticals	**414.7**	397.6	17.1	4.3	420.5	(5.8)	(1.4)	Ethical drugs domestic sales 1.1 Ethical drugs overseas sales 4.9 Contracted manufacturing products (1.9) Licensing fee, etc. 13.1 See page 5, "Sales of Main Products"
% Composition	**98.9%**	97.6%			98.9%			
Domestic	**369.1**	371.9	(2.8)	(0.7)	382.0	(12.9)	(3.4)	
Overseas	**45.6**	25.7	19.9	77.5	38.5	7.1	18.5	
Others	**4.5**	9.6	(5.1)	(53.2)	4.5	0.0	(0.2)	Decrease due to transfer of fine chemical operations
% Composition	**1.1%**	2.4%			1.1%			
Domestic	**2.4**	7.0	(4.6)	(66.1)	2.0	0.4	18.2	
Overseas	**2.1**	2.6	(0.5)	(19.1)	2.5	(0.4)	(14.8)	
Total	**419.2**	407.2	12.0	3.0	425.0	(5.8)	(1.4)	Overseas sales ratio FY2011: 7.0% FY2012: 11.4% Average exchange rate FY2011: 1$= ¥79.63 FY2012: 1$= ¥82.61
% Composition	**100.0%**	100.0%			100.0%			
Domestic	**371.4**	378.8	(7.4)	(1.9)	384.0	(12.6)	(3.3)	
Overseas	**47.7**	28.3	19.4	68.5	41.0	6.7	16.4	

(3) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	FY2012	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		FY2011	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %	
Cost of sales	**166.4**	152.3	14.1	9.3	167.0	(0.6)	(0.4)	The sales cost ratio is worsened due to the drug price revision, etc.
% of Net sales	**39.7%**	37.4%			39.3%			
SG&A expenses	**183.8**	185.8	(2.0)	(1.1)	188.0	(4.2)	(2.2)	
% of Net sales	**43.9%**	45.6%			44.2%			
R&D expenses	**66.5**	70.2	(3.7)	(5.3)	70.0	(3.5)	(5.0)	Decrease in one-time payment for licensing-in, etc.
% of Net sales	**15.9%**	17.3%			16.5%			
Except R&D expenses	**117.3**	115.6	1.7	1.5	118.0	(0.7)	(0.6)	
Labor cost	**51.9**	52.0	(0.1)	(0.1)	51.5	0.4	0.8	
Amortization of goodwill	**10.3**	10.1	0.2	1.6	10.2	0.1	0.9	
Others	**55.1**	53.5	1.6	3.0	56.3	(1.2)	(2.1)	Increase in amortization of selling rights, etc.
Total labor cost	**90.0**	88.8	1.2	1.4	89.0	1.0	1.2	

*1: Published forecasts announced on Oct. 29, 2012 in the financial results for 2nd quarter of FY2012

(4) Non-operating Income and Loss

[Billion yen]

	FY2012	FY2011	Increase (Decrease)	Notes
Non-operating income	**4.5**	3.5	1.0	
Interest income	**1.7**	1.6	0.1	
Dividend income	**0.8**	0.8	0.0	
Equity in earnings of affiliates	**0.4**	0.2	0.2	
Rent income	**0.3**	0.2	0.1	
Others	**1.3**	0.7	0.6	
Non-operating expenses	**4.1**	3.8	0.3	
Foreign exchange loss	**1.1**	1.5	(0.4)	
Adjustment for salaries for employees on secondment	**0.5**	-	0.5	
Donations	**0.5**	0.4	0.1	
Loss on disposal of property, plant and equipment	**0.4**	0.4	0.0	
Others	**1.5**	1.5	0.1	

(5) Extraordinary Income and Loss

[Billion yen]

	FY2012	FY2011	Increase (Decrease)	Notes
Extraordinary income	**4.2**	1.2	3.1	
Gains on sales of property, plant and equipment	**3.0**	0.7	2.2	FY2012: Sanban-cho office, Tokyo, etc.
Gains on sales of investments in securities	**0.9**	-	0.9	
Gains on transfer of business	**0.4**	-	0.4	Gain on transfer of fine chemical operations
Reversal of reserve for loss on disaster	**-**	0.5	(0.5)	
Extraordinary Loss	**5.9**	6.1	(0.2)	
Loss on business integration	**2.3**	-	2.3	Loss according to integration of plasma fracnation operations
Provision of reserve for HCV litigation	**2.0**	-	2.0	Additional transfer according to the extension of the Relief Law
Impairment loss	**0.8**	3.3	(2.6)	FY2012: Hirakata reserch office, Nabari No.2 training center, etc. FY2011: Sanban-cho office, Tokyo
Loss on sale of investments in securities	**0.4**	-	0.4	Choseido Pharmaceutical
Loss on valuation of investment in securities	**0.3**	2.2	(1.9)	
Special retirement expenses	**-**	0.1	(0.1)	
Loss on disaster	**-**	0.1	(0.1)	
Others	**0.3**	0.4	(0.1)	

(6) Taxes

[Billion yen]

	FY2012	FY2011	Increase (Decrease)
Income before income taxes and minority interests	**67.7**	63.8	3.9
Income taxes-current	**26.9**	20.0	6.9
Income taxes-deferred	**(1.2)**	4.5	(5.7)
Minority interests	**0.1**	0.2	(0.2)
Net Income	**41.9**	39.0	2.9

Notes	FY2012	FY2011
Statutory tax rate	37.9%	40.6%
Adjustment		
Non-deductible expenses	1.4%	2.8%
Non-taxable dividend income, etc.	(1.7%)	(1.9%)
Adjustment for per capital inhabitants tax	0.3%	0.2%
Special deduction for R&D expenses	(5.3%)	(9.2%)
Amortization of goodwill	5.7%	6.4%
Elimination of dividends upon consolidation	1.5%	1.6%
Increase/decrease in valuation allowance	2.0%	(0.2%)
Adjustment on deferred tax assets due to change in tax rate	-	(1.3%)
Others	0.2%	(0.5%)
Actual tax rate	38.0%	38.5%

(7) Sales of Main Products

[Billion yen]

	FY2012	Y-on-Y			Comparison to Forecasts		
		FY2011	Increase (Decrease)	Change %	Forecasts *1	Increase (Decrease)	Change %
Ethical drugs	**409.4**	392.2	17.2	4.4	415.0	(5.6)	(1.3)
Ethical drugs domestic sales	**356.6**	355.4	1.1	0.3	369.0	(12.4)	(3.4)
Remicade	**73.5**	66.3	7.2	10.8	75.0	(1.5)	(2.0)
Ceredist	**18.4**	18.0	0.4	2.3	19.0	(0.6)	(3.1)
Talion	**14.3**	13.3	1.0	7.3	15.0	(0.7)	(4.5)
Maintate	**14.1**	13.7	0.4	3.1	15.0	(0.9)	(5.9)
Radicut	**13.3**	22.5	(9.2)	(41.0)	14.0	(0.7)	(5.2)
Anplag	**13.0**	15.3	(2.3)	(15.0)	13.5	(0.5)	(4.0)
Urso	**13.3**	14.5	(1.2)	(8.2)	13.5	(0.2)	(1.5)
Kremezin	**12.2**	11.7	0.5	4.5	12.5	(0.3)	(2.5)
Venoglobulin IH	**11.0**	10.7	0.3	2.6	11.5	(0.5)	(4.6)
Depas	**10.4**	11.0	(0.6)	(5.8)	10.5	(0.1)	(1.3)
Telavic	**5.1**	1.5	3.7	245.9	8.5	(3.4)	(39.5)
Herbesser	**7.6**	8.7	(1.0)	(11.9)	7.5	0.1	1.6
Tanatril	**7.1**	8.3	(1.2)	(14.7)	7.0	0.1	1.6
Lexapro	**4.6**	1.3	3.3	262.3	5.5	(1.0)	(17.3)
Simponi	**5.3**	1.0	4.3	453.6	7.0	(1.7)	(24.6)
Liple	**5.1**	6.2	(1.1)	(18.0)	5.0	0.1	1.8
Neuart	**4.4**	5.4	(0.9)	(17.7)	4.5	(0.1)	(1.8)
BIKEN Products [Vaccine]	**28.8**	28.8	0.0	(0.1)	29.5	(0.7)	(2.4)
Mearubik	**8.0**	9.5	(1.5)	(15.9)	8.0	0.0	0.3
Influenza	**7.7**	9.0	(1.4)	(15.1)	8.5	(0.8)	(9.8)
JEBIK V	**4.8**	7.1	(2.4)	(33.0)	6.0	(1.2)	(20.3)
Tanabe Seiyaku Hanbai Products *2	**19.0**	17.5	1.5	8.5	19.0	0.0	(0.2)
Ethical drugs overseas sales *3	**23.4**	18.5	4.9	26.7	23.5	(0.1)	(0.5)
Herbesser	**5.9**	4.9	1.1	22.1	6.0	(0.1)	(0.9)
Argatroban (Novastan)	**2.9**	3.1	(0.2)	(6.4)	2.5	0.4	15.2
Tanatril	**2.1**	1.7	0.4	20.5	2.0	0.1	2.8
Vaccine	**1.8**	1.6	0.2	13.5	2.0	(0.2)	(10.3)
Contracted manufacturing products *4	**6.8**	8.7	(1.9)	(21.7)	7.0	(0.2)	(3.0)
Lincensing Fee, etc.	**22.7**	9.6	13.1	136.2	15.5	7.2	46.3
Royalty from Gilenya	**19.5**	5.6	13.9	246.3	-	-	-
OTC products	**5.3**	5.4	(0.1)	(2.1)	5.5	(0.2)	(3.9)
Total Pharmaceuticals	**414.7**	397.6	17.1	4.3	420.5	(5.8)	(1.4)

*1: Published forecasts announced on October 29, 2012 in the financial results for 2nd quarter of FY2012.

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*3: In 2012, the settling days of overseas subsidiaries are changed from end of December to that of March, thus their accounting periods are for fifteen months from January, 2012 to March, 2013.

*4: Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of FY2012	Composition %	End of FY2011	Increase (Decrease)	Notes
Total Aseets	**866.8**	**100.0**	819.9	46.8	
Current Assets	**476.7**	**55.0**	419.7	57.0	
Cash and deposits	**20.3**	**2.3**	15.5	4.8	See Page 7, (2) Cash Flows Statement
Marketable securities	**64.0**	**7.4**	46.3	17.6	Increase in negotiable deposits and corporate bond, etc
Notes and accounts receivable*1	**129.9**	**15.0**	127.2	2.7	
[Months/Revolution]	**[3.72]**		[3.75]	[(0.03)]	
Inventories	**92.8**	**10.7**	86.2	6.6	Increase in products, such as Remicade and vaccine
Deposits	**151.6**	**17.5**	130.8	20.8	
Deferred income taxes	**8.4**	**1.0**	9.3	(1.0)	
Others	**9.8**	**1.1**	4.3	5.5	
Fixed Assets	**390.1**	**45.0**	400.3	(10.2)	
Property, plant and equipment	**92.3**	**10.6**	103.9	(11.6)	Investment for plant and equipment, 9.2; Depreciation, (7.3); Decrease due to integration of plasma fractionation operations (6.3), etc.
Intangible fixed assets	**104.2**	**12.0**	109.4	(5.2)	Investment for information system, 2.2; Record and amortization of goodwill accompanied with the acquisition of Bipha stocks, 4.1; Amortization of goodwill of the merger, (10); Depreciation, (1.1)
Investment in securities	**121.0**	**14.0**	116.6	4.4	Increase due to market value, increase in corporate bond, decrease in government bond, decrease due to the transfer of Choseido Pharmaceutical stocks
Long-term prepaid expenses	**10.2**	**1.2**	14.4	(4.1)	
Prepaid pension expenses	**36.9**	**4.3**	42.1	(5.2)	
Deferred income taxes	**4.2**	**0.5**	7.9	(3.7)	
Other investments	**21.4**	**2.5**	6.0	15.4	
Total Liabilities	**113.9**	**13.1**	98.4	15.4	
Current Liabilities	**86.1**	**9.9**	69.6	16.5	
Notes and accounts payable*2	**38.1**	**4.4**	28.9	9.2	Increase in debts for Remicade, plasma fracnations and vaccine, etc
Short-term debt	**1.2**	**0.1**	2.2	(1.0)	
Accounts payable, other	**15.6**	**1.8**	15.7	(0.1)	
Income taxes payable	**16.2**	**1.9**	6.7	9.5	
Other current liabilities	**15.1**	**1.7**	16.1	(1.0)	
Long-term Liabilities	**27.7**	**3.2**	28.9	(1.1)	
Deferred income taxes	**8.4**	**1.0**	9.3	(1.0)	
Accrued retirement benefits for employees	**9.4**	**1.1**	10.6	(1.1)	
Reserve for health management allowances for HIV compensation	**1.6**	**0.2**	1.5	0.2	
Reserve for health management allowances for SMON compensation	**3.2**	**0.4**	3.6	(0.5)	
Reserve for HCV litigation	**3.6**	**0.4**	2.5	1.1	Reversal accompanied with payment of the settlement
Other long-term liabilities	**1.5**	**0.2**	1.3	0.2	Transfer according to the extension of the Relief Law, reversal accompanied with payment of the settlement
Net Assets	**752.9**	**86.9**	721.5	31.4	
Shareholders' equity	**744.3**	**85.9**	724.9	19.5	
Common stock	**50.0**	**5.8**	50.0	-	
Capital surplus	**451.2**	**52.1**	451.2	-	
Retained earnings	**243.6**	**28.1**	224.2	19.5	Net income, 41.9; Payment for dividends, (22.4)
Teasury stock, at cost	**(0.5)**	**(0.1)**	(0.5)	0.0	
Accumulated other comprehensive loss	**3.6**	**0.4**	(9.1)	12.7	
Unrealized holding (losses) gains on securities	**7.2**	**0.8**	(0.1)	7.3	
Deffered (losses) gains on hedges	**1.6**	**0.2**	0.1	1.5	
Translation adjustments	**(5.2)**	**(0.6)**	(9.1)	3.9	
Minority interests	**5.0**	**0.6**	5.7	(0.7)	

*1: Note and accounts receivable = Bills + Accounts receivable

*2: Note and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	FY2012	FY2011	Increase (Decrease)
Cash and cash equivalents at beginning of year	**54.3**	97.9	(43.5)
Cash flows from operating activities	**60.6**	37.2	23.3
Income before income taxes and minority interests	**67.7**	63.8	3.9
Depreciation and amortization	**8.4**	12.5	(4.0)
Loss on impairment of fixed assets	**0.8**	3.3	(2.6)
Amortization of goodwill	**10.3**	10.1	0.2
Increase (decrease) in accrued retirement benefit for employees	**(1.2)**	(1.3)	0.1
Decrease (increase) in prepaid pension expenses	**5.2**	(1.7)	6.9
Increase (decrease) in reserve for HCV litigation	**1.1**	(2.1)	3.2
Increase (decrease) in allowance for disaster	**0.0**	(1.5)	1.5
Interest and dividend income	**(2.5)**	(2.4)	(0.1)
Loss (gain) on transfer of business	**(0.4)**	-	(0.4)
Loss (gain) on sale of investment in securities	**0.3**	2.2	(1.9)
Loss on business integration	**2.3**	-	2.3
Decrease(increase) in notes and accounts receivable, trade	**(1.9)**	1.0	(2.9)
Decrease (increase) in inventories	**(17.7)**	(8.6)	(9.1)
Increase (decrease) in notes and accounts payable, trade	**8.6**	(0.6)	9.1
Increase(decrease) in accounts payable, other	**(0.7)**	(2.1)	1.4
Interest and dividends received	**2.7**	2.5	0.2
Income taxes paid	**(17.9)**	(28.4)	10.5
Other, net	**(4.5)**	(9.6)	5.2
Cash flows from investing activities	**(35.0)**	(63.2)	28.3
Purchase/sales etc. of marketable securities	**(9.3)**	43.2	(52.5)
Increase/decrease in time deposits	**0.4**	9.3	(8.9)
Increase in deposits	**(20.7)**	(110.8)	90.0
Increase/decrease in long-term deposits	**1.9**	(0.4)	2.3
Purchase/sales of property, plant and equipment	**1.5**	(7.3)	8.8
Purchase of intangible fixed assets	**(2.1)**	(1.2)	(0.9)
Purchase/sales of investment in securities	**(0.5)**	4.0	(4.6)
Purchase of investment in subsidiaries	**(6.0)**	-	(6.0)
Proceeds from transfer of business	**1.4**	-	1.4
Other, net	**(1.3)**	0.0	(1.3)
Cash flows from financing activities	**(23.7)**	(17.2)	(6.5)
Increase (decrease) in short-term debt, net	**(1.2)**	(0.7)	(0.5)
Cash dividends paid	**(22.4)**	(16.3)	(6.2)
Other, net	**0.0**	(0.2)	0.1
Effect of exchange rate change on cash and cash equivalents	**2.5**	(0.4)	2.9
Net increase (decrease) in cash and cash equivalents	**4.4**	(43.5)	47.9
Cash and cash equivalents at end of the year	**58.7**	54.3	4.4

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	FY2012	FY2011
Cash and time deposits	20.3	15.5
Time deposits maturing after three months	(2.4)	(2.5)
Short-term investments in marketable securities maturing within three months of acquisition	20.6	21.2
Cash equivalents included in short-term loans receivable*	0.2	0.1
Cash equivalents included in deposits	20.1	20.0
Cash and cash equivalents in the consolidated statements of cash flows	58.7	54.3

*: Short-term loans are included in "Others, Current Assets" on page 6.

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	FY2012	FY2011	Increase (Decrease)
Investment in property, plant and equipment /occuring basis	9.2	7.1	2.2
Investment in information systems/occuring basis	2.2	1.2	0.9

Major investment in property, plant and equipment in FY2012		Major investment in development of imformation sysytems in FY2012	
Mitsubishi Tanabe Pharma	5.0	Mitsubishi Tanabe Pharma	2.0
[Enhancement of pilot plant at Kashima]	[0.7]		
Mitsubishi Tanabe Pharma Factory	2.5		

(4) Depreciation Costs

[Billion yen]

	FY2012	FY2011	Increase (Decrease)
Property, plant and equipment	7.3	11.4	(4.1)
Intangible fixed assets	1.1	1.0	0.1

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

	Companies	Mitsubishi Tanabe Pharma Factory Ltd.*	Tanabe Seiyaku Hanbai Co., Ltd*	Mitsubishi Tanabe Pharma Korea Co., Ltd.*	Mitsubishi Pharma (Guangzhou) Co., Ltd.*	Tianjin Tanabe Seiyaku Co., Ltd.*	P.T. Tanabe Indonesia*
Net Sales	FY2012	**52.4**	**19.0**	**4.2**	**1.2**	**3.4**	**2.4**
	FY2011	54.9	17.5	3.7	0.1	2.1	1.9
Operating Income	FY2012	**2.2**	**1.0**	**0.3**	**(1.0)**	**0.1**	**0.3**
	FY2011	3.2	1.2	0.2	(0.9)	0.0	0.4
Ordinary Income	FY2012	**1.9**	**1.0**	**0.4**	**(1.0)**	**0.1**	**0.3**
	FY2011	3.4	1.2	0.2	(1.0)	0.1	0.4
Net Income and Loss	FY2012	**1.3**	**0.5**	**0.3**	**(1.0)**	**0.1**	**0.1**
	FY2011	1.9	1.1	0.2	(1.0)	0.0	0.3
R&D Expenses	FY2012	**1.1**	**-**	**-**	**0.0**	**-**	**-**
	FY2011	0.9	-	-	-	0.0	0.0
Depreciation of Property, Plant and Equipment	FY2012	**2.0**	**0.0**	**0.1**	**0.1**	**0.1**	**0.1**
	FY2011	3.6	0.0	0.1	0.1	0.1	0.1
Total Assets	FY2012	**63.7**	**8.5**	**2.7**	**4.7**	**2.4**	**2.1**
	FY2011	58.4	7.4	2.2	3.0	1.8	1.9
Net Assets	FY2012	**39.7**	**0.5**	**2.1**	**2.6**	**1.8**	**1.5**
	FY2011	39.4	0.0	1.5	2.2	1.4	1.3
Number of Employees	FY2012	**1369**	**164**	**122**	**444**	**430**	**455**
	FY2011	1238	166	125	425	392	424

*: In 2012, the settling days of overseas subsidiaries are changed from end of December to that of March, thus their accounting periods are for fifteen months from January, 2012 to March, 2013. In China, however, the legal settling day should be end of December and its revision is not allowed. Therefore, provisional settlement of account is used in Mitsubishi Pharma (Guangzhou) and Tianjin Tanabe Seiyaku.

3 Forecasts for FY2013 Ending March 31, 2014

(Amounts less than ¥100 million are rounded.)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	1st Half of FY2013 Forecasts	1sy Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %	Notes
Net Sales	**200.0**	203.8	(3.8)	(1.9)	**417.0**	419.2	(2.2)	(0.5)	
Cost of Sales	**78.0**	79.3	(1.3)	(1.6)	**163.0**	166.4	(3.4)	(2.0)	
Sales cost ratio	**39.0%**	38.9%			**39.1%**	39.7%			
Gross Operatin Profit	**122.0**	124.6	(2.6)	(2.1)	**254.0**	252.8	1.2	0.5	
SG & A Expenses	**92.0**	92.3	(0.3)	(0.3)	**184.0**	183.8	0.2	0.1	
% of Net Sales	**46.0%**	45.3%			**44.1%**	43.9%			
Operating Income	**30.0**	32.2	(2.2)	(7.0)	**70.0**	69.0	1.0	1.5	
Ordinary Income	**31.0**	33.1	(2.1)	(6.4)	**71.5**	69.4	2.1	3.0	
Extraordinary Income or loss	**(1.0)**	(2.4)	1.4	-	**(2.5)**	(1.7)	(0.8)	-	
Net Income	**19.0**	19.5	(0.5)	(2.5)	**44.0**	41.9	2.1	5.0	

(2) Sales Forecasts by Segments

[Billion yen]

	1st Half of FY2013 Forecasts	1sy Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %	Notes
Pharmaceuticals	**199.3**	200.7	(1.4)	(0.7)	**415.7**	414.7	1.0	0.2	
% Composition	**99.7%**	98.5%			**99.7%**	98.9%			
Domestic	**175.7**	183.4	(7.7)	(4.2)	**365.6**	369.1	(3.5)	(0.9)	
Overseas	**23.6**	17.4	6.2	35.8	**50.1**	45.6	4.5	9.9	
Other Businesses	**0.7**	3.1	(2.4)	(77.4)	**1.3**	4.5	(3.2)	(71.1)	
% Composition	**0.4%**	1.5%			**0.3%**	1.1%			
Domestic	**0.2**	2.0	(1.8)	(90.2)	**0.5**	2.4	(1.9)	(78.8)	
Overseas	**0.5**	1.1	(0.6)	(52.7)	**0.8**	2.1	(1.3)	(62.4)	
Total	**200.0**	203.8	(3.8)	(1.9)	**417.0**	419.2	(2.2)	(0.5)	Foreign sales ratio FY2012: 11.4% FY2013 estimation: 12.2%
% Composition	**100.0%**	100.0%			**100.0%**	100.0%			
Domestic	**175.9**	185.4	(9.5)	(5.1)	**366.1**	371.4	(5.3)	(1.4)	Exchange rate planned: 1US$=¥95
Overseas	**24.1**	18.4	5.7	30.7	**50.9**	47.7	3.2	6.6	

(3) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	1st Half of FY2013 Forecasts	1sy Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %	Notes
Cost of Sales	**78.0**	79.3	(1.3)	(1.6)	**163.0**	166.4	(3.4)	(2.0)	
Sales cost ratio	**39.0%**	38.9%			**39.1%**	39.7%			
SG & A Expenses	**92.0**	92.3	(0.3)	(0.3)	**184.0**	183.8	0.2	0.1	
% of Net sales	**46.0%**	45.3%			**44.1%**	43.9%			
R&D Expenses	**35.4**	34.2	1.2	3.4	**70.5**	66.5	4.0	6.0	
% of Net sales	**17.7%**	16.8%			**16.9%**	15.9%			
Except R&D Expenses	**56.6**	58.1	(1.5)	(2.6)	**113.5**	117.3	(3.8)	(3.2)	
Labor Cost	**23.8**	26.0	(2.2)	(8.3)	**47.9**	51.9	(4.0)	(7.7)	
Amortization of Goodwill *	**5.2**	5.1	0.1	2.7	**10.4**	10.3	0.1	1.0	
Others	**27.6**	27.1	0.5	2.0	**55.2**	55.1	0.1	0.2	
Total Labor Cost	**41.6**	45.1	(3.5)	(7.7)	**83.5**	90.0	(6.5)	(7.3)	

(4) Sales Forecasts for Main Products [Billion yen]

	1st Half of FY2013 Forecasts	1st Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %
Ethical drugs	**196.6**	197.9	(1.3)	(0.7)	**410.5**	409.4	1.1	0.3
Ethical drugs domestic sales	**169.7**	176.6	(6.9)	(3.9)	**354.5**	356.6	(2.1)	(0.6)
Remicade	**38.6**	36.7	1.9	5.1	**78.6**	73.5	5.1	6.9
Ceredist	**9.0**	9.5	(0.5)	(5.5)	**18.2**	18.4	(0.2)	(1.1)
Maintate	**7.5**	7.0	0.5	7.6	**15.8**	14.1	1.7	11.9
Talion	**5.4**	5.3	0.1	2.4	**15.7**	14.3	1.4	9.6
Kremezin	**6.3**	6.0	0.3	4.9	**13.1**	12.2	0.9	7.5
Urso	**5.9**	6.8	(0.9)	(12.7)	**12.1**	13.3	(1.2)	(9.0)
Venoglobulin IH	**5.7**	5.5	0.2	2.8	**11.7**	11.0	0.7	6.6
Anplag	**5.9**	6.8	(0.9)	(13.3)	**11.6**	13.0	(1.4)	(10.5)
Radicut	**5.0**	7.0	(2.0)	(28.3)	**9.8**	13.3	(3.5)	(26.2)
Depas	**4.7**	5.3	(0.6)	(11.2)	**9.5**	10.4	(0.9)	(8.3)
Simponi	**4.1**	2.2	1.9	84.1	**9.2**	5.3	3.9	74.4
Lexapro	**3.3**	1.7	1.6	98.4	**8.3**	4.6	3.8	82.4
Herbesser	**3.6**	3.9	(0.3)	(8.0)	**7.0**	7.6	(0.6)	(8.2)
Tanatril	**3.3**	3.7	(0.4)	(10.7)	**6.3**	7.1	(0.8)	(11.4)
BIKEN Products [Vaccine]	**12.7**	12.6	0.1	0.6	**27.9**	28.8	(0.9)	(3.1)
Tetrabik	**4.3**	-	4.3	-	**9.0**	4.5	4.5	98.6
Influenza	**1.4**	1.5	(0.1)	(8.8)	**8.1**	7.7	0.4	5.7
Tanabe Seiyaku Hanbai Products *1	**6.7**	9.1	(2.4)	(26.2)	**14.0**	19.0	(5.0)	(26.2)
Ethical drugs overseas sales *3	**10.9**	10.2	0.7	7.3	**21.1**	23.4	(2.3)	(9.8)
Herbesser	**2.4**	2.3	0.1	4.3	**4.9**	5.9	(1.0)	(17.6)
Argatroban (Novastan)	**0.9**	1.4	(0.5)	(35.3)	**1.8**	2.9	(1.1)	(37.5)
Tanatril	**0.9**	0.9	0.0	4.0	**1.7**	2.1	(0.4)	(17.3)
Contracted manufacturing products *3	**3.0**	3.8	(0.8)	(20.5)	**5.6**	6.8	(1.2)	(17.5)
Lincensing Fee, etc.	**13.0**	7.4	5.6	76.3	**29.3**	22.7	6.6	29.3
OTC products	**2.7**	2.8	(0.1)	(3.8)	**5.2**	5.3	(0.1)	(1.7)
Total Pharmaceuticals	**199.3**	200.7	(1.4)	(0.7)	**415.7**	414.7	1.0	0.2

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2:In 2012, the settling days of overseas subsidiaries are changed from end of December to that of March, thus their accounting periods are for fifteen months from January, 2012 to March, 2013.

*3: Active pharmaceutical ingredients and others ordered by other companies.

(5) Forecasts of Investment for Property, Plant and Equipment and Information Systems

[Billion yen]

	1st Half of FY2013 Forecasts	1st Half of FY2012 Actual	Increase (decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occuring basis	8.5	4.2	4.3	100.2	13.7	9.2	4.5	48.1
Investment for information systems/occuring basis	1.6	1.0	0.6	53.4	2.8	2.2	0.6	28.7

[Billion yen]

Major investment in property, plant and equipment in FY2013		Major investment for information systems in FY2013	
Production facilities	7.8	R&D related Systems	1.0
Facilities & equipment for R&D	3.5	Production related system	0.1
Others	2.4	Others	1.7

(6) Forecasts for Depreciation Costs

[Billion yen]

	1st Half of FY2013 Forecasts	1st Half of FY2012 Actual	Increase (decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (decrease)	Change %
Property, plant and equipment	3.9	3.8	0.1	3.1	8.1	7.3	0.8	10.7
Intangible fixed assets	0.6	0.6	0.0	3.4	1.3	1.1	0.2	16.1

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2008	FY2009	FY2010	FY2011	FY2012	Forecast for FY2013
Net sales	414.8	404.7	409.5	407.2	419.2	417.0
Cost of sales	158.2	147.8	154.6	152.3	166.4	163.0
Gross operation profit	256.6	256.9	255.0	254.9	252.8	254.0
SG&A expenses	184.9	195.5	178.4	185.8	183.8	184.0
R&D expenses	73.1	83.1	65.8	70.2	66.5	70.5
Operating income	71.7	61.5	76.6	69.0	69.0	70.0
Ordinary income	72.6	61.6	76.7	68.8	69.4	71.5
Extraordinaly income	1.2	0.1	0.6	1.2	4.2	(2.5)
Extraordinaly loss	25.8	10.8	13.2	6.1	5.9	
Net income	26.5	30.3	37.7	39.0	41.9	44.0

(2) Balance Sheet

[Billion yen]

	End of FY2008	End of FY2009	End of FY2010	End of FY2011	End of FY2012
Total assets	810.8	796.9	818.7	819.9	866.8
Current assets	364.4	344.2	391.6	419.7	476.7
Fixed assets	446.3	452.6	427.1	400.3	390.1
Total liabilities	144.5	120.0	122.7	98.4	113.9
Current liabilities	89.2	77.8	87.7	69.6	86.1
Fixed liabilities	55.4	42.3	35.0	28.9	27.7
Net assets	666.2	676.8	696.0	721.5	752.9

(3) Other Financial Data

[Billion yen]

	FY2008	FY2009	FY2010	FY2011	FY2012	Forecast for FY2013
Cash flows from operating activities	50.5	23.9	59.1	37.2	60.6	-
Cash flows from investing activities	(74.5)	(61.2)	(7.7)	(63.2)	(35.0)	-
Cash flows from financing activities	(16.0)	(17.1)	(15.4)	(17.2)	(23.7)	-
Investments in property, plant and equipment	12.2	8.4	10.2	7.1	9.2	13.7
Investments for development of information systems	1.7	0.8	0.8	1.2	2.2	2.8
Depreciation costs	15.7	13.3	12.4	12.5	8.4	9.4
Equity ratio (%)	80.5	84.1	84.3	87.3	86.3	-
ROE (%)	4.1	4.6	5.5	5.5	5.7	-
Net income per share (¥)	47.28	53.91	67.27	69.54	74.67	78.43
Net assets per share (¥)	1,162.69	1,194.79	1,230.16	1,275.85	1,333.22	-

(4) Number of Employees

	End of FY2008	End of FY2009	End of FY2010	End of FY2011	End of FY2012	Forecast End of 2013
Consolidated	10,030	9,266	9,198	9,180	8,835	9,110
Non-consolodated	5,715	5,186	4,957	4,826	4,850	4,850

5 Quaterly Trend

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2011					FY2012					FY2013
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2011 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Oct. to Dec.	FY2012 Actual	Forecast
Net sales	102.3	98.1	115.4	91.4	407.2	104.4	99.4	118.7	96.6	419.2	417.0
	25.1%	24.1%	28.3%	22.5%	100.0%	24.9%	23.7%	28.3%	23.0%	100.0%	
Domestic	95.7	91.5	108.0	83.6	378.8	95.6	89.8	105.2	80.8	371.4	366.1
	25.3%	24.1%	28.5%	22.1%	100.0%	25.7%	24.2%	28.3%	21.8%	100.0%	
Overseas	6.6	6.6	7.4	7.8	28.3	8.8	9.6	13.5	15.8	47.7	50.9
	23.1%	23.5%	25.9%	27.5%	100.0%	18.4%	20.2%	28.3%	33.1%	100.0%	
Pharmaceuticals	99.8	95.7	112.9	89.2	397.6	101.9	98.8	118.2	95.8	414.7	415.7
	25.1%	24.1%	28.4%	22.4%	100.0%	24.6%	23.8%	28.5%	23.1%	100.0%	
Domestic	93.7	89.8	106.2	82.1	371.9	93.7	89.7	105.1	80.7	369.1	365.6
	25.2%	24.2%	28.6%	22.1%	100.0%	25.4%	24.3%	28.5%	21.9%	100.0%	
Overseas	6.0	5.8	6.7	7.2	25.7	8.2	9.2	13.1	15.1	45.6	50.1
	23.4%	22.7%	26.0%	27.8%	100.0%	18.0%	20.1%	28.8%	33.1%	100.0%	
Others	2.5	2.4	2.5	2.2	9.6	2.5	0.6	0.6	0.8	4.5	1.3
	26.1%	25.4%	25.7%	22.8%	100.0%	54.9%	13.9%	12.5%	18.7%	100.0%	
Domestic	2.0	1.6	1.8	1.6	7.0	1.9	0.1	0.2	0.2	2.4	0.5
	28.3%	23.4%	26.0%	22.4%	100.0%	80.4%	5.8%	7.3%	6.6%	100.0%	
Overseas	0.5	0.8	0.7	0.6	2.6	0.6	0.5	0.4	0.7	2.1	0.8
	20.3%	30.9%	24.9%	23.9%	100.0%	26.7%	23.0%	18.2%	32.2%	100.0%	
Cost of sales	37.4	37.1	44.9	33.0	152.3	40.6	38.6	47.5	39.7	166.4	163.0
Sales Cost Ratio	36.5%	37.8%	38.9%	36.1%	37.4%	38.9%	38.8%	40.0%	41.0%	39.7%	39.1%
Gross operating profit	64.9	61.0	70.5	58.5	254.9	63.7	60.8	71.3	57.0	252.8	254.0
	25.5%	23.9%	27.7%	22.9%	100.0%	25.2%	24.1%	28.2%	22.5%	100.0%	
SG&A expenses	42.2	47.7	46.6	49.3	185.8	44.9	47.4	44.7	46.8	183.8	184.0
	22.7%	25.7%	25.1%	26.6%	100.0%	24.4%	25.8%	24.3%	25.5%	100.0%	
R&D expenses	15.7	17.8	18.1	18.6	70.2	16.9	17.3	17.0	15.3	66.5	70.5
	22.4%	25.4%	25.7%	26.5%	100.0%	25.4%	26.0%	25.5%	23.0%	100.0%	
Non-R&D expenses	26.4	29.9	28.6	30.7	115.6	28.0	30.1	27.7	31.5	117.3	113.5
	22.9%	25.9%	24.7%	26.6%	100.0%	23.9%	25.7%	23.6%	26.9%	100.0%	
Labor costs	12.6	13.3	12.9	13.1	52.0	12.9	13.0	12.5	13.5	51.9	47.9
	24.3%	25.6%	24.9%	25.2%	100.0%	24.9%	25.1%	24.0%	25.9%	100.0%	
Amortization of goodwill	2.5	2.5	2.5	2.5	10.1	2.5	2.5	2.6	2.6	10.3	10.4
	25.0%	25.0%	25.0%	25.0%	100.0%	24.6%	24.6%	25.5%	25.3%	100.0%	
Others	11.3	14.1	13.1	15.1	53.5	12.5	14.5	12.6	15.5	55.1	55.2
	21.1%	26.3%	24.5%	28.2%	100.0%	22.8%	26.3%	22.8%	28.1%	100.0%	
Operating income	22.7	13.3	23.9	9.1	69.0	18.8	13.4	26.6	10.1	69.0	70.0
	32.9%	19.3%	34.6%	13.2%	100.0%	27.3%	19.4%	38.6%	14.7%	100.0%	
Ordinary income	23.0	13.4	24.0	8.4	68.8	19.6	13.5	27.0	9.3	69.4	71.5
	33.4%	19.5%	34.9%	12.2%	100.0%	28.3%	19.4%	38.9%	13.3%	100.0%	
Net income	11.4	8.5	15.9	3.2	39.0	10.8	8.7	15.8	6.6	41.9	44.0
	29.3%	21.9%	40.7%	8.1%	100.0%	25.8%	20.7%	37.6%	15.9%	100.0%	

The each figure (excluding Cost of sales) in the lower displays the progress rate.

v. Quaterly Trend (Sales of Main Products)

[Billion yen]

	FY2011					FY2012					FY2013
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2011 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2012 Actual	Forecast
Ethical drugs	98.3	94.2	111.4	88.2	392.2	100.6	97.4	116.7	94.8	409.4	410.5
	25.1%	24.0%	28.4%	22.5%	100.0%	24.6%	23.8%	28.5%	23.1%	100.0%	
Ethical drugs domestic sales	89.8	85.9	102.9	76.8	355.4	90.5	86.1	102.0	78.0	356.6	354.5
	25.3%	24.2%	28.9%	21.6%	100.0%	25.4%	24.1%	28.6%	21.9%	100.0%	
Remicade	15.8	16.2	18.9	15.3	66.3	17.9	18.8	19.8	17.0	73.5	78.6
	23.9%	24.5%	28.5%	23.1%	100.0%	24.4%	25.6%	27.0%	23.1%	100.0%	
Ceredist	4.7	4.3	5.1	4.0	18.0	5.0	4.5	5.0	3.9	18.4	18.2
	25.9%	23.7%	28.4%	22.0%	100.0%	27.2%	24.6%	27.0%	21.3%	100.0%	
Talion	3.1	2.3	3.9	4.1	13.3	3.1	2.2	3.7	5.3	14.3	15.7
	22.9%	16.9%	29.3%	30.9%	100.0%	21.3%	15.5%	25.8%	37.3%	100.0%	
Maintate	3.4	3.2	4.1	3.1	13.7	3.6	3.3	4.0	3.2	14.1	15.8
	24.9%	23.3%	29.6%	22.3%	100.0%	25.8%	23.6%	28.1%	22.6%	100.0%	
Radicut	6.7	6.1	5.9	3.8	22.5	3.7	3.3	3.7	2.6	13.3	9.8
	29.9%	26.9%	26.4%	16.7%	100.0%	28.0%	24.6%	27.7%	19.8%	100.0%	
Anplag	4.1	3.6	4.5	3.1	15.3	3.7	3.1	3.5	2.7	13.0	11.6
	26.8%	23.7%	29.4%	20.1%	100.0%	28.3%	24.3%	27.0%	20.5%	100.0%	
Urso	3.8	3.4	4.2	3.1	14.5	3.5	3.3	3.7	2.9	13.3	12.1
	26.2%	23.6%	28.9%	21.3%	100.0%	26.3%	24.6%	27.6%	21.6%	100.0%	
Kremezin	2.8	3.3	2.9	2.6	11.7	3.1	2.9	3.5	2.7	12.2	13.1
	24.4%	28.6%	24.8%	22.1%	100.0%	25.7%	23.6%	28.7%	22.0%	100.0%	
Venoglobulin IH	2.5	2.6	3.3	2.4	10.7	2.9	2.7	3.2	2.2	11.0	11.7
	23.3%	23.8%	30.6%	22.2%	100.0%	26.1%	24.4%	29.2%	20.3%	100.0%	
Depas	2.8	2.6	3.1	2.4	11.0	2.8	2.5	2.8	2.2	10.4	9.5
	25.5%	24.0%	28.3%	22.2%	100.0%	26.7%	24.4%	27.4%	21.5%	100.0%	
Telavic	-	-	0.2	1.3	1.5	2.1	1.3	1.0	0.6	5.1	4.0
	-	-	12.0%	88.0%	100.0%	41.8%	25.7%	20.0%	12.6%	100.0%	
Herbesser	2.3	2.0	2.5	1.8	8.7	2.1	1.8	2.1	1.6	7.6	7.0
	27.0%	23.6%	28.8%	20.6%	100.0%	27.7%	23.7%	27.9%	20.8%	100.0%	
Tanatril	2.3	2.0	2.4	1.7	8.3	2.0	1.7	2.0	1.5	7.1	6.3
	27.3%	24.0%	28.6%	20.1%	100.0%	27.7%	24.3%	27.6%	20.5%	100.0%	
Lexapro	-	0.4	0.4	0.5	1.3	0.8	0.9	1.4	1.5	4.6	8.3
	-	34.9%	28.0%	37.1%	100.0%	16.5%	20.0%	31.0%	32.5%	100.0%	
Simponi	-	0.0	0.4	0.5	1.0	1.0	1.2	1.6	1.5	5.3	9.2
	-	5.0%	38.4%	56.6%	100.0%	19.7%	22.5%	29.5%	28.3%	100.0%	
Liple	1.7	1.5	1.7	1.3	6.2	1.4	1.2	1.4	1.1	5.1	4.4
	26.6%	23.9%	28.1%	21.4%	100.0%	27.5%	23.8%	27.6%	21.1%	100.0%	
Neuart	1.3	1.3	1.7	1.1	5.4	1.2	1.1	1.4	0.8	4.4	4.3
	23.9%	23.9%	31.6%	20.6%	100.0%	26.4%	24.2%	30.7%	18.7%	100.0%	
BIKEN products [Vaccine]	7.0	8.1	9.4	4.3	28.8	6.1	6.5	11.4	4.8	28.8	27.9
	24.4%	28.0%	32.7%	14.8%	100.0%	21.3%	22.6%	39.5%	16.6%	100.0%	
Mearubik	4.2	2.1	1.2	2.1	9.5	3.4	2.1	0.7	1.9	8.0	3.7
	43.6%	22.2%	12.3%	21.9%	100.0%	41.9%	25.6%	9.2%	23.3%	100.0%	
Influenza	0.0	2.3	6.4	0.3	9.0	0.0	1.6	6.8	(0.7)	7.7	8.1
	(0.1%)	26.0%	71.2%	3.0%	100.0%	(0.5%)	20.5%	88.7%	(8.7%)	100.0%	
JEBIK V	2.1	2.8	1.3	1.0	7.1	1.8	1.8	0.6	0.6	4.8	4.1
	29.3%	39.3%	18.0%	13.4%	100.0%	37.4%	37.3%	11.7%	13.6%	100.0%	
Tanabe Seiyaku Hanbai products *1	4.4	3.8	5.2	4.1	17.5	4.8	4.2	5.5	4.3	19.0	14.0
	24.9%	22.0%	29.8%	23.3%	100.0%	25.5%	22.3%	29.2%	22.9%	100.0%	
Ethical drugs overseas sales *2	4.7	4.5	4.7	4.6	18.5	4.5	5.6	5.0	8.2	23.4	21.1
	25.3%	24.2%	25.5%	24.9%	100.0%	19.5%	24.0%	21.6%	35.0%	100.0%	
Herbesser	1.2	1.1	1.3	1.3	4.9	1.1	1.2	1.1	2.5	5.9	4.9
	24.6%	22.5%	27.1%	25.7%	100.0%	19.3%	19.4%	19.1%	42.2%	100.0%	
Argatroban (Novastan)	1.0	0.7	0.8	0.6	3.1	0.7	0.7	0.5	1.0	2.9	1.8
	32.3%	21.1%	25.6%	21.0%	100.0%	24.8%	23.5%	17.2%	34.6%	100.0%	
Tanatril	0.4	0.5	0.5	0.4	1.7	0.5	0.4	0.4	0.8	2.1	1.7
	22.9%	28.2%	27.7%	21.3%	100.0%	21.9%	20.2%	20.6%	37.3%	100.0%	
Vaccine	0.5	0.5	0.3	0.3	1.6	0.3	0.7	0.6	0.2	1.8	-
	29.8%	29.1%	21.0%	20.0%	100.0%	15.2%	41.1%	34.7%	9.0%	100.0%	
Contracted manufacturing products *3	2.5	2.3	1.8	2.1	8.7	1.7	2.1	1.3	1.7	6.8	5.6
	28.3%	26.9%	20.2%	24.6%	100.0%	25.3%	30.2%	18.8%	25.6%	100.0%	
Lincensing fee, etc.	1.4	1.5	2.1	4.6	9.6	3.8	3.6	8.4	6.9	22.7	29.3
	15.0%	15.2%	21.9%	47.9%	100.0%	16.7%	15.9%	37.2%	30.3%	100.0%	
OTC products	1.4	1.5	1.5	1.0	5.4	1.4	1.5	1.5	1.0	5.3	5.2
	26.4%	27.0%	27.3%	19.3%	100.0%	25.6%	27.5%	27.8%	19.1%	100.0%	
Total pharmaceuticals	99.8	95.7	112.9	89.2	397.6	101.9	98.8	118.2	95.8	414.7	415.7
	25.1%	24.1%	28.4%	22.4%	100.0%	24.6%	23.8%	28.5%	23.1%	100.0%	

The each figure in the lower displays the progress rate.

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2: In 2012, the settling days of overseas subsidiaries are changed from end of December to and of March, thus their accounting periods are for fifteen month from January, 2012 to March, 2013.

*3: Active pharmaceutical ingredients and others ordered by other companies.

6 State of New Product Development (As of May 8, 2013)

1. Pipeline in Japan

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin	Notes
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Phase 3	In-house	
MP-214 (Cariprazine)	D3/D2 receptor partial agonist (Schizophrenia)	Phase 2b/3	Hungary: Gedeon-Richter	
MT-4666	α7nACh receptor agonist (Dementia of Alzheimer's type)	Phase 2	US: EnVivo	
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Phase 1	In-house	
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Phase 1	In-house	

(2) Additional Indications

Product name (Generic name)	Category (Indications)	Stage	Origin	Notes
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	sNDA filed (Sep. 2012)	Switzerland: Merck Serono	
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	sNDA filed (Feb. 2013)	In-house	
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house	
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Phase 3	Japan: Ube Industries	
	(Pediatric atopic dermatitis)	Phase 3		
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [genotype2])	Phase 3	US:Vertex	
	(Chronic hepatitis C, [combination with Pegasys])	Phase 3		
	(Chronic hepatitis C, [combination with Feron])	Phase 3		
Remicade (Infliximab [recombinant])	Anti-human TNFα monoclonal antibody (Refractory Kawasaki disease*)	Phase 3	US:Janssen Biotech	
	(Behcet's disease with special lesions*)	Phase 3		
	(Pediatric Crohn's disease)	Phase 3		
	(Pediatric ulcerative colitis)	Phase 3		
	(Psoriasis: increased dose)	Phase 3		
Imusera (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	P3	In-house	Co-developed with Novartis Pharma, Multinational study
Cholebine (Colestimide[JAN])	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house	
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1		

* Orphan drug designated

2. Pipelines Overseas

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Taiwan	Filed (Jan. 2013)	US:Vertex
		Korea	Phase 1	
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha
MT-9938 (Nalfurafine)	κ-opioid receptor agonist (Refractory pruritus)	US	Phase 2	Japan:Toray
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house
		US	Phase 1	
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house
MP-157	Angiotensin Type 2 receptor agonist (Hypertention)	Europe	Phase 1	In-house

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Europe	MAA filed (Mar. 2012)	US: Vivus
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	Europe	MAA filed (Jun. 2012)	US: Janssen Pharmaceuticals
	(Type2 diabetes mellitus / fixed dose combination with metformin, IR)	US	NDA filed (Dec. 2012)	
	(Type2 diabetes mellitus / fixed dose combination with metformin, IR)	Europe	MAA filed (Mar. 2013)	
	(Obesity)	US, Europe	Phase 2	
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	Phase 3	Korea: Handok Pharmaceuticals
FTY720 (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Multinational study	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
T-0047 (Firategrast)	Cell adhesion inhibitor [α4β7/α4β1 inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK: GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US: MediciNova
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
MCC-847	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma/Sidem
TT-138	β3 receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US: MediciNova
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism)	Japan	Phase 1	Japan: Kyowa Hakko Kirin
Wf-516	SSRI / 5HT1A receptor antagonists (Depression)	Europe	Phase 1	US: SONKEI Pharmaceuticals
Y-803	Bromodomain inhibitor (Hematological cancer)	US, Europe	Phase 1	Switzerland: OncoEthix (Development code: OTX015)

4. Changes Since Previous Announcement on Feb. 1, 2013

(1) In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of February 1, 2013	As of May 8, 2013
Omeprazon (Omeprazole)	Proton pump inhibitor (Hericobacter pylori eradication by concomitant therapy for Hericobacter pylori gastritis)	Japan	sNDA filed (Aug. 2012)	Approved (Feb. 2013)
Grtpa (Alteplase[recombinant])	Thrombolytic agent (Acute ischemic cerebrovascular disease [up to 4.5 hours after the onset of symptoms])	Japan	sNDA filed (Sep. 2012)	Approved (Feb. 2013)
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	Japan	Phase 3	sNDA filed (Feb. 2013)
Imusera (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Multinational study *	None	Phase 3
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric atopic dermatitis)	Japan	None	Phase 3
MP-424/Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [combination with Pegasys])	Japan	None	Phase 3
	(Chronic hepatitis C, [combination with Feron])	Japan	None	Phase 3
	(Chronic hepatitis C)	Korea	None	Phase 1
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 1	Phase 2
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 1	Phase 2
MP-435	C5a receptor antagonist (Rheumatoid arthritis)	Japan	Phase 2	Discontinued
MT-7716	NOP receptor agonist (Alcohol-use disorder)	US	Phase 1	Discontinued

(2) Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of February 1, 2013	As of May 8, 2013
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	US	NDA filed (May 2012)	Approved (March, 2013)
	(Type2 diabetes mellitus / Fixed Dose Combination with Metformin (IR))	US	None	NDA filed (Dec. 2012)
	(Type2 diabetes mellitus / Fixed Dose Combination with Metformin (IR))	Europe	None	MAA filed (March, 2013)
FTY720 (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Multinational study *	None	Phase 3
Y-803	Bromodomain inhibitor (hematological cancer)	US, Europe	None	Phase 1

* Co-developed with Novartis Pharma in Japan

5. Additional Information for State of New Product Development (as of May 8, 2013)

(1) New Molecular Entities in Japan

Development code (Generic name)	Information
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. Clinical stage is Phase 3 for type2 diabetes mellitus.
MP-214 (Cariprazine)	MP-214 is a dopamine D3/D2 receptor partial agonist, licensed from Gedeon-Richter (Hungary). Clinical stage is Phase 2b/3 for schizophrenia.
MT-4666	MT-4666 is an α7 nACh receptor agonist, licensed from EnVivo(US). Clinical stage is Phase 2 for dementia of Alzheimer's type.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase 1.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist. Clinical stage is Phase1 as a succesor of Imusera/Gilenya.

(2) Additional Indications in Japan

Product name (Generic name)	Information
Maintate (Bisoprolol)	(Chronic atrial fibrillation) Maintate is a selective β1 antagonist. It was launched as a treatment for hypertension, angina and premature ventricular beat in 1990. An additional indication for heart failure was approved in 2011. sNDA has been filed for chronic atrial fibrillation with data of clinical trial, responding the request from the academic society.
Tenelia (Teneligliptin)	Tenelia is developed for the treatment of type2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP-4), thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. It was launched in September, 2012. An applicayion for additional combination therapy was filed.
Radicut (Edaravone)	(Amyotrophic lateral sclerosis [Orphan drug designated in June, 2005]) Radicut is a free radical scavenger. In 2001, it was launched for improvement neurological symptoms at the acute stage of cerebral infarction, interference with activities of daily living and functional disability. Clinical stage is Phase 3.
Talion (Bepotastine)	It was launched as an anti-allergic agent for adult in 2000. (Pediatric allergic rhinitis) Clinical stage is Phase 3.
	(Pediatric atopic dermatitis) Clinical stage is Phase 3.
Telavic (Telaprevir)	It was launched as a treatment for chronic hepatitis C in 2011. (Chronic hepatitis C [genotype2]) Clinical stage is Phase 3.
	(Chronic hepatitis C, [combination with Pegasys]) Clinical stage is Phase 3.
	(Chronic hepatitis C, [combination with Feron]) Clinical stage is Phase 3.
Remicade (Infliximab[recombinant])	Remicade is an anti-human TNFα monoclonal antibody. It was launched as a treatment for Crohn's disease in 2002, followed by as a treatment for rheumatoid arthritis, intractable uveoretinitis caused by Behcet's disease, psoriasis, ankylosing spondylitis, and ulcerative colitis. (Refractory Kawasaki disease [Orphan drug designated in September, 2012]) Clinical stage is Phase 3.
	(Behcet's disease with special lesions [Orphan drug designated in September, 2012]) Clinical stage is Phase 3.
	(Pediatric Crohn's disease) Clinical stage is Phase 3.
	(Pediatric ulcerative colitis) Clinical stage is Phase 3.
	(Psoriasis: inceased dose) Clinical stage is Phase 3.
Imusera (Fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. It had been jointly developed with Novaltis Pharma for the domestic market. It was launched as a treatment for multiple sclerosis in 2011. (Chronic inflammatory demyelinating polyradiculoneuropathy) Clinical stage is Phase 3, multinational study. It has been jointly developed with Novaltis Pharma for the domestic market.
Cholebine (Colestimide[JAN])	Cholebine is a bile acid eliminant. It was launched as a treatment for hypercholesterolemia in 1999. (Type 2 diabetes mellitus) Clinical stage is Phase 2.
	(Hyperphosphatemia) Clinical stage is Phase 1.

(3) New Molecular Entities in Overseas

Development code (Generic name)	Information
MP-424 (Telaprevir)	MP-424 is NS3-4A protease inhibitor, licensed from Vertex (US). It was launched as a treatment for chronic hepatitis C in Japan under the brand name TELAVIC®.
MP-146	MP-146 is spherical carbon adsorbent, licensed from KUREHA (Japan) in November 2006. Clinical stage is Phase 3 for chronic kidney disease patients in Europe, North America and Latin America. It had been marketed by Daiichi Sankyo in Japan from 1991 under the brand name, KREMEZIN®. In April 2011, Mitsubishi Tanabe Pharma succeeded its marketing from Daiichi Sankyo.
MT-9938 (Nalfurafine)	MT-9938 is κ-opioid receptor agonist, licensed from Toray (Japan). Clinical stage is Phase 2 as a refractory pruritus in the US.
MP-513 (Teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. Clinical stages in the US and Europe are Phase 1 and Phase 2, respectively. It has been marketed in Japan for the treatment of type2 diabetes mellitus in September 2012, under the brand name of TENELIA®.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase 2 in Europe.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist as a succesor of Imusera/Gilenya. (Multiple sclerosis) Clinical stage is Phase 2
GB-1057 (Recombinant human serum albumin)	GB-1057 is a recombinant human serum albumin. Clinical stage is Phase 1 as a stabilizing agent in the US.
MP-124	MP-124 is a PARP inhibitor that has neuroprotective effect. Clinical stages in the US and Canada are Phase 1.
MP-157	MP-157 is an angiotensin type2 receptor agonist. Clinical stage is Phase 1 in Europe.

(4) Licensing-out

Development code (Generic name)	Information
TA-1790 (Avanafil)	TA-1790 is created for the treatment of erectile dysfunction which is expected to have a quick onset and fewer side effects. In Europe, MAA was filed by Vivus.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. In Europe, MAA was submitted by Janssen Pharmaceuticals in June 2012. It has been marketed in the US for the treatment of type2 diabetes mellitus, under the brand name of INVOKANA™. NDA, in the US in Dec. 2012, and MAA, in Europe in March 2013, were submitted for the fixed dose combination with metformin, IR. Phase 2 clinical trials in obesity in Europe and the US are completed.
MP-513 (Teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. Phase 3 is conducting by Handok in Korea.
FTY720 (Fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. It was launched as a treatment for multiple sclerosis under the brandname of Imusera by Mitsubishi Tanabe Pharma in Japan. It is also marketed under the brand name of Gilenya by Novartis. (Chronic inflammatory demyelinating polyradiculoneuropathy) Multinational study is Phase 3, co-development with Novartis Pharma in Japan.
T-0047 (Firategrast)	T-0047 inhibits the cell adhesion and cell migration processes of white blood cells in inflammatory region. Phase 2 is conducted by GSK in Europe, etc.
MKC-242	MKC-242 is a serotonin 1A receptor agonist, used to treat psychiatric disorders such as anxiety and depression. This compound is expected to express rapid onset with low possibility of dependency. MediciNova (US) is conducting Phase 2 for insomnia.
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscles. Clinical stage is Phase 2 in Japan by Senju Pharmaceutical.
MT-210	MT-210 is a 5-HT2A/ Sigma 2 receptor antagonist. Clinical stage is Phase 2 in Europe by Cyrenaic (France).
TA-7906	TA-7906 is a PDE4 inhibitor. Clinical stage is Phase 2 for the treatment of atopic dermatitis in Japan by Maruho.
MCC-847 (Masilukast)	Leukotriene D4 receptor antagonist. Clinical stage is Phase 2 for the treatment of asthma in Korea by SAMA Pharma (Korea).
sTU-199 (Tenatoprazole)	sTU-199 is an isomer of TU-199, developed in Japan, and licensed to Negma (France). Pharmacokinetic/pharmacodynamic results from Phase 1 in Europe and the US demonstrated that sTU-199 controlled gastric acid secretion at nighttime in patients receiving this compound once-daily, with the long half-life. It is expected that this compound could reveal rapid improvement for non-erosive reflux disease. Sidem Pharma, a subsidiary of Negma, is conducting phase 1 in Europe.
TT-138	TT-138 is a β3 receptor agonist used to treat pollakiuria and urinary incontinence. Phase 1 is conducted by MediciNova in the US.
MT-4580	Ca sensing receptor agonist. Clinical stage is Phase 1 for the treatment of secondary hyperparathyroidism in Japan by Kyowa Hakko Kirin (Japan).
Wf-516	SSRI / 5HT1A receptor antagonists. Clinical stage is Phase 1 for the treatment of depression in Europe by SONKEI Pharmaceuticals (US).
Y-803	Bromodomain inhibitor. Clinical stage is Phase 1 for the treatment of hematological cancer in the US and Europe by OncoEthix (Switzerland).

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of FY2012	End of FY2011	Increase (Decrease)	Notes
Consolidated subsidiaries	**28**	28	-	
Non-consolidated subsidiaries	**1**	3	(2)	Decrease: Choseido Pharmaceutical, Hoshienu Pharmaceutical
Affiliated companies	**3**	3	-	
Total	**32**	34	(2)	

(2) Consolidated Subsidiaries [As of March 31, 2013]

	Company Name	Paid-in Capital (Million yen)	% Voting Control	[% Indirect Ownership]	Settling Day	Description of Business
1	Benesis Corporation	100	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
2	Mitsubishi Tanabe Pharma Factory Ltd.	1,130	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
3	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
4	Mitsubishi Pharma (Guangzhou) Co., Ltd.	US$23,500,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
5	Tianjin Tanabe Seiyaku Co., Ltd.	US$12,000,000	66.7	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
6	Yoshitomiyakuhin Corporation	385	100.0	[-]	End of Mar.	Provision of information about pharmaceuticals
7	MP-Logistics Corporation	95	65.0	[-]	End of Mar.	Distribution, warehouse operations
8	Bipha Corporation	100	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
9	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	400	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
10	Tanabe Seiyaku Hanbai., Ltd.	169	100.0	[-]	End of Mar.	Sale of generic pharmaceuticals, etc.
11	Tanabe R&D Service Co., Ltd.	44	100.0	[-]	End of Mar.	Support of R&D regarding pharmaceuticals
12	Tanabe Total Service Co., Ltd.	90	100.0	[-]	End of Mar.	Real estate management, etc.
13	MP Healthcare Venture Management, Inc.	US$100	65.0	[-]	End of Mar.	Investments in bio-ventures
14	Mitsubishi Tanabe Pharma Holdings America, Inc.	US$166	100.0	[-]	End of Mar.	Management of group companies in US
15	Mitsubishi Tanabe Pharma Development America, Inc.	US$100	100.0	[100.0]	End of Mar.	R&D of pharmaceuticals
16	Tanabe Research Laboratories U.S.A., Inc.	US$3,000,000	100.0	[100.0]	End of Mar.	R&D of pharmaceuticals
17	Tanabe U.S.A., Inc.	US$1,400,000	100.0	[100.0]	End of Mar.	Sale of chemicals, etc.
18	Mitsubishi Tanabe Pharma America, Inc.	US$100	100.0	[100.0]	End of Mar.	Sale of pharmaceuticals
19	Mitsubishi Pharma Research & Development (Beijing) Co., Ltd.	US$1,000,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
20	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0	[-]	End of Dec.	Sale of pharmaceuticals
21	Taiwan Tanabe Seiyaku Co., Ltd.	NT$90,000,000	65.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
22	Tai Tien Pharmaceuticals Co., Ltd.	NT$20,000,000	65.0	[-]	End of Mar.	Sale of pharmaceuticals
23	P.T. Tanabe Indonesia	US$2,500,000	99.6	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
24	Mitsubishi Pharma Europe Ltd.	£4,632,000	100.0	[-]	End of Mar.	R&D of pharmaceuticals
25	Mitsubishi Pharma Deutschland GmbH	EUR 25,000	100.0	[100.0]	End of Mar.	Sale of pharmaceuticals
26	Tanabe Europe N.V.	EUR 260,330	100.0	[-]	End of Mar.	Sale of chemicals, etc.

Note: Aside from the companies mentioned above, there are two consolidated companies under the liquidations.

(3) Affiliated Companies Accounted for by the Equity Method [As of March 31, 2013]

	Company Name	Paid-in Capital (Million yen)	% Voting Control	[% Indirect Ownership]	Settling Day	Description of Business
1	API Corporation	4,000	47.7	[-]	End of Mar.	Manufacture and sale of API, etc.
2	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	End of March, 2013	End of March, 2012
Issued	**561,417,916**	561,417,916
The company's own shares at the end of the period	**424,977**	423,532
Number of shares outstanding at the end of the period	**560,992,939**	560,994,384
Average number of the company's own share in the period	**423,959**	364,350
Average number of shares outstanding in the period	**560,993,957**	561,053,566

(2) Status of Major Shareholders

Rank	Name of Shareholders	End of March, 2013		End of March, 2012		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	Japan Trustee Services Bank, Ltd.	31,890	5.68%	2	32,566	5.80%
3	The Master Trust of Japan, Ltd.	26,640	4.75%	3	28,150	5.01%
4	Nippon Life Insurance Company	15,116	2.69%	4	15,137	2.70%
5	Nipro Corporation	7,642	1.36%	5	7,642	1.36%
6	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	6	7,254	1.29%
7	JP Morgan Chase Bank, N.A., 385147	7,100	1.26%	7	7,100	1.26%
8	Employee Stock Ownership Plan	4,747	0.85%	8	4,423	0.79%
9	Goldman Sachs & Company Regular Account	4,583	0.82%	9	4,297	0.77%
10	Tokyo Marine & Nichido Fire Insurance Co., Ltd.	4,175	0.74%	10	4,175	0.74%

(3) Ownership and Distribution of Shares

	End of March, 2013			End of March, 2012		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial institutions	81	104,341	18.59%	64	106,350	18.95%
Foreign corporations and others	388	86,473	15.41%	375	82,524	14.70%
Individuals and others	16,331	29,397	5.24%	13,850	27,518	4.90%
Other corporations	286	339,197	60.43%	282	342,629	61.04%
Securities firms	44	1,900	0.34%	57	2,285	0.41%
Total	17,130	561,311	100.00%	14,628	561,308	100.00%
Less than trading unit	-	106	-	-	109	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stock (424 thousands shares at the end of March, 2013 and 423 thousands shares at the end of March, 2012)

(4) Trend of Divinded and Stock Price

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2013 Estimate
Dividends per share (yen)	28	28	28	35	40	40
Dividend payout ratio(%)	59.2	51.9	41.6	50.3	53.6	51.0
(prior to amortization of goodwill)	(43.0)	(39.0)	(32.9)	(40.0)	(43.2)	(41.5)
Stock price at the end of FY	971	1,320	1,350	1,161	1,445	-
Market capitalization (billion yen)	5,451	7,411	7,579	6,518	8,112	-

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNFα monoclonal antibody
Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of rheumatoid arthritis, Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addtion, in July 2009 and August 2011, changes in usage/dosage were approved for rheumatoid arthritis, and Crohn's disease, respectively. Origin: Jannsen Biotech			
Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration
Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. An additional formulation, orally disintegrating tablets, was launched in October 2009.			
Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders
Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007. Origin: Ube Industries			
Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias)
Maintate is a representative β -blocker used in more than 100 countries around the world. It exhibits high selectivity for β 1 receptor and excellent phamacokinetics profiles. It has high efficacy and safety, and there is evidence for its cardioprotective action. Additional indications for chronic heart failure has been approved in May 2011, and for chronic atrial fibrillation has been filed in September 2012. Origin: Merck Serono			
Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)
Radicut is the world's first brain protecting agent (free radical scavemger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administrated for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was launched in May 2010.			
Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)
Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels.			
Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions
Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in the human body. Urso has effects of hapatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.			
Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure
Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC. Origin, Manufacturer and distributor: Kureha			
Venoglobulin IH (Human immunoglobulin)	Launch: Jan. 1992	Category	Plasma derivatives
Venoglobulin IH is intravenous human immunoglobulin derived from donated plasma in Japan. It shows high efficacy on serious infectious diseases in combined administration with an anti-bacterial agent due to its opsonic, immuno-bacteriolytic and antibody-dependent cytotoxic effects and neutralizing effects on toxics and viruses. In October 2010 and September 2011, the indications for improvement of muscle weakness associated with polymyositis or dermatomyositis and generalized myasthenia gravis (only in case of insufficient response to steroids or immunosuppressants) were added, respectively. It is expected to be a new treatment option for the diseases that contribute better QOL for patients.			
Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent
Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.			

Telavic (Telaprevir)	Launch: Nov. 2011	Category	NS3-4A protease inhibitor

Teravic is positioned in the first-in-class oral drug for treating chronic hepatitis C. It inhibits hepatitis C virus (HCV) proliferation by inhibiting NS3-4A protease which involved in HCV replication. It was revealed that the combination therapy of three drugs (pegylated interferon, ribavirin and Teravic) improves therapeutic efficacy and shortens the treatment period, compared to the current standard therapy, for the patients with chronic hepatitis C affected by genotype 1 virus. In addition, it is expected to offer the new treatment opportunity to patients for whom the conventional treatment was not effective.
Origin: Vertex

Herbesser (Diltiazem)	Launch: Feb. 1974	Category	Calcium antagonist (Treatment of angina pectoris and hypertension)

Herbesser is a representative calcium antagonist that is used in more than 110 countries around the world. In addition to a blood pressure lowering effect, it has a cardioprotective action in patients with hypertension or angina pectoris by reducing the cardiac load through a heart rate lowering effect and by increasing the oxygen supply through a coronary vasodilating effect.

Tanatril (Imidapril)	Launch: Dec. 1993	Category	ACE inhibitor (Treatment of hypertension)

Tanatril shows excellent blood pressure control with effective organ protection as well as minimal incidence of dry cough, a common side effect of ACE inhibitors. With the approval of an additional indication in January 2002, it became the first drug in Japan approved for diabetic nephropathy with type I diabetes mellitus.

Lexapro (Escitalopram)	Launch: Aug. 2011	Category	Selective sertonin reuptake inhibitor (SSRI)

Lexapro is a selective serotonin reuptake inhibitor with high selectivity of serotonin transporter, and available in more than 96 countries and regions. By having good efficacy and tolerability, in addition to simple administration, it is expected to contribute to the improvement of medication adherence for patients with depression.
Origin: H. Lundbeck, Manufacturer and distributor: Mochida Pharmaceutical

Simponi (Golimumab)	Launch: Sep. 2011	Category	Anti-TNFα monoclonal antibody

Simponi is a human anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis (including prevention of articular structural damage), and co-marketed with Janssen Pharmaceutical. It shows a long acting efficacy by subcutaneous injection once every four weeks, and currently is under development for the ulcerative colitis by Janssen Pharmaceutical.
Origin: Janssen Biotech

Liple (Arprostadil)	Launch: Nov. 1988	Category	Agent for treatment of Chronic arterial occlusion / Circulatory disturbance (PGE1)

Liple, the world's first DDS (Drug Delivery System) agent of intravenous PGE1, improves the peripheral circulatory disturbance and skin ulcer in chronic arterial occlusive disease and diabetes by its direct vasodilating effects. DDS maximizes the therapeutic effects and simultaneously minimizes the adverse effects of PGE1.

Neuart (Anti-thrombin III)	Launch: Jun. 1987	Category	Plasma derivatives (Anticoagulant agent)

Neuart is highly purified human anti-thrombin III derived from donated plasma in Japan. It shows strong anticoagulant effects in the treatment of DIC patients by inhibiting various kinds of activated serine protease including thrombin.

Mearubik (Live Attenuated Measles and Rubella Vaccine)	Launch: Dec. 2005	Category	Prevention of measles and rubella

Mearubik is the combination vaccine for measles and rubella, and children are able to receive both measles and rubella shot at a time with Mearubik, which is used at the 1st term and the 2nd term of its regular vaccination. By both reducing the number of injections and relieving physical pain on people to be vaccinated, it is expected to contribute enhancement of immunization rate for measles and rubella in Japan.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

JEBIK V (Cell Culture-derived Japanese Encephalitis Vaccine)	Launch: Jan. 2009	Category	Prevention of Japanese encephalitis

JEBIK V is a freeze-dried preparation containing inactivated Japanese encephalitis virus derived from Vero cells which were used in the manufacturing process as a host to increase the virus. It is used at the 1st term and 2nd term of the regular vaccination. It is expected to reduce the occurrence of ADEM by not using mice's brains in the manufacturing process.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

TETRABIK (Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine)	Launch: Oct. 2012	Category	Prevention of pertussis, diphtheria, tetanus and acute poliomyelitis (polio)

TETRABIK is a combined vaccine that prevents acute poliomyelitis (polio), pertussis, diphtheria and tetanus. It is used at 1st term (initial 3 times) and 1st term (additional 1 time), in total 4 times, of the regular vaccination. By using TETRABIK, It is expected to avoid the very rare occurrence of paralytic symptoms similar to those in natural polio due to live-attenuated oral polio vaccine.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

News Releases

The major news releases after October 2012 are as follows.
Please refer to the Company's website for the details. (http://www.mt-pharma.co.jp/e/release/index.php)

Date	Contents
October 1, 2012	Outsourcing of Logistics Operations
October 10, 2012	Outcome of Global Phase III (EPPIC) Studies for Treatment of Chronic Kidney Disease
October 19, 2012	Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.
October 26, 2012	Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine
January 29, 2013	BindRen Granted Marketing Authorization in Europe for Treatment of Hyperphosphatemia
February 21, 2013	Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
February 26, 2013	Application for Additional Combination Therapy for TENELIA, a Treatment for Type2 Diabetes Mellitus
February 28, 2013	Approval for Time-window Extension of the Thrombolytic Agents GRTPA and ACTIVACIN up to 4.5 Hours after the Onset of Symptoms of Ischemic Cerebrovascular Disease
April 1, 2013	U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes
April 1, 2013	Transfer of Tanabe Europe’s shares
April 3, 2013	Launch of BindRen for Treatment of Hyperphosphatemia in Germany and Austria